Search

Your search keyword '"Robin Filshie"' showing total 5 results
Start Over Author "Robin Filshie" Journal leukemia & lymphoma
5 results on '"Robin Filshie"'

1. Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic

Author

Aditya Tedjaseputra, James A. Kuzich, Nisha Thiagarajah, Tse-Chieh Teh, Julia McClelland, Marzia Rahman, Rowena Brook, Chong Chyn Chua, Doen Ming Ong, Shuh-Ying Tan, Robin Filshie, Chun Yew Fong, Pasquale Fedele, Ashish Bajel, Jake Shortt, and Andrew H. Wei

Subjects
Leukemia, Myeloid, Acute, Cancer Research, Oncology, Leukocytosis, Acute Disease, Humans, COVID-19, Hematology, Pandemics
Published
2022

2. Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy

Author

Robin Filshie, Maciej Tatarczuch, Hang Quach, Constantine S. Tam, Amanda Tey, Matthew Ku, Erin Paul, Ali Bazargan, Jake Shortt, Gareth P. Gregory, Stephen Opat, and Michael Gilberston

Subjects
Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Disease, Transplantation, Autologous, Central Nervous System Neoplasms, 03 medical and health sciences, 0302 clinical medicine, Autologous stem-cell transplantation, Primary CNS Lymphoma, Older patients, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Aged, Chemotherapy, business.industry, Cytarabine, Hematopoietic Stem Cell Transplantation, Brain, Hematology, medicine.disease, Combined Modality Therapy, Lymphoma, Radiation therapy, Methotrexate, 030220 oncology & carcinogenesis, business, Stem Cell Transplantation, 030215 immunology, medicine.drug
Abstract

Primary CNS lymphoma (PCNSL) in immunocompetent patients is a disease of older adults who are often unsuitable for the high dose therapy or experience substantial morbidity from whole brain radiotherapy. As therapeutic studies in older patients are limited, there is a need for real world data to guide patient care. Here we report a series of 38 consecutive immunocompetent patients with PCNSL treated with curative intent using R-MPV/Ara-C with omission of consolidative radiotherapy in older patients. Outcomes for patients aged60 years and60 years were similar with overall response rates of 100% vs 85%, (

Published
2020

3. Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy

Author

David Westerman, Thomas E Lew, Chan Yoon Cheah, John F. Seymour, Ali Bazargan, Max Wolf, Robin Filshie, Constantine S. Tam, H. Miles Prince, E. Henry Januszewicz, and Dennis A. Carney

Subjects
Male, Cancer Research, medicine.medical_specialty, Cyclophosphamide, Chronic lymphocytic leukemia, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Chemoimmunotherapy, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Dose Reduced, Aged, Neoplasm Staging, Aged, 80 and over, Chlorambucil, business.industry, Age Factors, Hematology, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Minimal residual disease, Fludarabine, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Immunology, Female, Rituximab, business, Vidarabine, 030215 immunology, medicine.drug
Abstract

Despite its efficacy in prospective trials, full dose fludarabine, cyclophosphamide and rituximab (FCR) may be too toxic for elderly patients with chronic lymphocytic leukemia (CLL) in clinical practice. We retrospectively reviewed the impact of dose reductions in FCR therapy on the outcomes of 42 consecutive patients aged 65-87 (median 72) years. Despite a median cumulative fludarabine dose reduction of 50% from full dose, the objective response and complete response rates were 86% and 38% respectively (frontline 94%/59%; previously treated 80%/24%). Dose reductions of 25-75% were not significantly associated with inferior progression free survival compared to minimal reductions (≤25%) (p=0.49), and did not preclude deep responses, including six cases (14%) of minimal residual disease negativity. Although hematological and infectious toxicities were common, treatment limiting adverse effects were infrequent. Dose attenuated FCR appears to have preserved efficacy and may be a viable therapeutic option for elderly patients with CLL.

Published
2015

4. Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma

Author

Robin Filshie, Kah-Lok Chan, Hang Quach, and Harshal Hanumant Nandurkar

Subjects
Cancer Research, medicine.medical_specialty, Thrombotic microangiopathy, Red Cell, Bortezomib, business.industry, Hematology, Microangiopathic hemolytic anemia, medicine.disease, Gastroenterology, Remission induction, Oncology, Thrombotic occlusion, hemic and lymphatic diseases, Internal medicine, medicine, Neoplasm staging, business, Multiple myeloma, medicine.drug
Abstract

Thrombotic microangiopathy (TMA) is a serious medical condition that results from microvascular thrombotic occlusion, leading to red cell fragmentation (microangiopathic hemolytic anemia) and profo...

Published
2015

5. Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone

Author

Edward Chew, Andrew H. Wei, and Robin Filshie

Subjects
Oncology, Cancer Research, medicine.medical_specialty, High dose dexamethasone, Bortezomib, business.industry, Hematology, Lung injury, medicine.disease, Respiratory failure, immune system diseases, hemic and lymphatic diseases, Internal medicine, medicine, Concurrent therapy, Stage (cooking), business, Multiple myeloma, medicine.drug
Abstract

Bortezomib, a proteosome inhibitor used for the treatment of multiple myeloma, was first approved by the US FDA on 13 May 2003. At that stage, one case of respiratory failure associated with the dr...

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results